RMEI Medical Education, LLC and Postgraduate Institute for Medicine:

Sunday, March 26th

11:00-12:30 - Les Goudes 1

Optimizing Outcomes in CMV and GVHD in Stem Cell Transplant Patients: A Focus on Leading Causes of Morbidity and Mortality

Industry sponsored and supported symposia

Jazz Pharmaceuticals:

Sunday, March 26th
15:00-16:30 - Endoume 1+2

A Nurse's Role in the Management of Acute Transplant Complications

​

Monday, March 27th
12:45-14:15 - Hall 2

The Changing Picture of Transplant Complications: Real-life Examples

 

Tuesday, March 28th
13:00-14:00 - Les Goudes 2

A Pharmacy Perspective on the Importance and Value of Effective Management of VOD in Post-HSCT Patients

Basilea:

Sunday, March 26th
15:00-16:30 - Auditorium

Insights and opportunities in IMD and haematological malignancies

​

Tuesday, March 28th
16:30-17:30 - Les Goudes 2

Emerging issues for pharmacists and new agents in the management of IMD in haematological malignancies

Pfizer:

Sunday, March 26th
11:00-12:30 - Hall 1

Advances in the management of aplastic anaemia: An interactive symposium

​

Sunday, March 26th

13:00-14:30 - Hall 1

Targeted approaches to improve outcomes in AML

​

Sunday, March 26th

17:00-18:45 - Les Goudes 2

Redefining the ALL landscape through innovation

Takeda:

Sunday, March 26th
15:00-16:30 - Hall 1

The pivotal role of proteasome inhibition in myeloma treatment

 

Tuesday, March 28th
12:45-14:15 - Hall 2

Time for change: Improving outcomes in CD30-positive lymphomas

Amgen:

Sunday, March 26th

13:00-14:30 - Les Goudes 1

Stem cell transplantation in multiple myeloma – Strategies and potential

​

Sunday, March 26th
15:00-16:30 - Les Goudes 1

Considering transplant and T-cell engaging therapy in ALL

Celgene:

Sunday, March 26th
17:00-18:00 - Amphithéâtre Callelongue

60 Minutes to Revisit Allo-Transplant in HR MDS and AML

 

Sunday, March 26th
18:00-19:00 - Amphithéâtre Callelongue

CAR-T Cell therapy: Today and tomorrow

​

Monday, March 27th
16:30-18:00 - Hall 2

How Can We Raise the Bar in the Management of Transplant-Eligible Multiple Myeloma Patients?

Sanofi-Genzyme:

Sunday, March 26th

11:00-13:00 - Amphithéâtre Callelongue

GVHD: What's new in 2017?

​

Sunday, March 26th

14:30-16:30 - Amphithéâtre Callelongue

Update on mobilization issues

Miltenyi Biotec:

Sunday, March 26th
13:00-15:00 - Les Goudes 2

Cellular therapy: Recent advances and future perspectives

Molmed:

Sunday, March 26th
11:00-12:30 - Hall 2

1956 – 2016: a long journey from the first successful BMT to the first successful patient-specific cell therapy in HSCT, approved by EC
 

Tuesday, March 28th

12:45-14:15 - Hall 1

Nurses role in cell therapy management

Mallinckrodt Pharmaceuticals (Therakos (UK) Ltd.):

Sunday, March 26th
17:00-19:00 - Les Goudes 1

ECP Immunomodulation: The importance of avoiding immune dysfunction and inducing tolerance for GvHD patients

​

Monday, March 27th
12:45-14:15 - Hall 1

Therakos Integrated Photopheresis: Value for Nurses and Patients through Education

IFM:

Sunday, March 26th

09:00-10:30 - Les Goudes 1

Multiple Myeloma in 2017: The IFM perspective

Janssen:

Sunday, March 26th
17:00-19:00 - Endoume 1+2+3

Novel agents in hematological malignancies: joining forces with transplantation?

Oxford Immunotec:

Sunday, March 26th
13:00-14:30 - Hall 2

Insights on New Developments in CMV Immune Monitoring and Alternative Therapies for HSCT Recipients

SFGM-TC:

Sunday, March 26th

09:00-10:30 - Les Goudes 2

Allo-HCT and pulmonary complications

Kiadis:

Sunday, March 26th
11:00-12:30 - Les Goudes 2

Advances in haploidentical stem cell transplantation and post-transplant immunotherapy

GSK:

Sunday, March 26th
15:00–16:30 - Hall 2

Pioneering progress in ADA-SCID with gene therapy

MSD:

Sunday, March 26th
09:00-10:30 - Auditorium

CMV infection in your hematology patient – what's standard, what's new?

 

Sunday, March 26th
11:00-12:30 - Auditorium

Fungal Infections in Transplant Recipients: Managing the Continuum of Risk

​

Sunday, March 26th
17:00-18:30 - Auditorium

A Novel Approach to prevent Recurrent C difficile Infections (CDI) in High Risk Patients